Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2022-11-29 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Neogene to be acquired by AstraZeneca
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and is clearly formatted as a regulatory news service announcement from the London Stock Exchange (LSE). The content details a significant corporate transaction: the acquisition of a portfolio company (Neogene) by AstraZeneca. This type of material—a major corporate event announcement disseminated via an official news service—is best classified as a general Regulatory Filing (RNS), as it does not fit the specific criteria for an Earnings Release (ER), Capital Update (CAP), or M&A Activity (TAR) which are usually more formal SEC filings or specific transaction documents. While it relates to M&A, RNS serves as the primary channel for immediate, broad regulatory disclosure in this context, and it is not a formal SEC filing like a 10-K or a proxy statement. Given the structure and source attribution ('This information is provided by RNS'), RNS is the most appropriate general classification.
2022-11-29 English
Syncona extends tender offer for AGTC
M&A Activity Classification · 100% confidence The document begins with an 'RNS Number' and is dated November 29, 2022. The content announces an extension of a tender offer by Syncona Limited for Applied Genetic Technologies Corporation (AGTC) shares. It details the terms, the new expiration time, and the current tender status. It also references filings made with the SEC (Schedule TO and Schedule 14D-9) and concludes with standard RNS disclaimers. This is a regulatory announcement regarding a corporate action (tender offer extension) distributed via the London Stock Exchange's RNS system. Since it is a specific corporate action announcement distributed via RNS, and not a full financial report (like 10-K or IR) or a general regulatory filing fallback (RNS), the most appropriate category is 'Regulatory Filings' (RNS) as it is a general regulatory announcement that doesn't fit the more specific corporate action codes like SHA or TAR, although it relates to M&A activity (TAR). However, given the structure and the explicit mention of RNS distribution and the nature of the announcement (an update on an ongoing offer), RNS serves as the best fit for this type of market news release, or potentially TAR if focusing on the M&A aspect. Since the document is a direct announcement distributed via RNS, and RNS is defined as the fallback for miscellaneous filings, I will use RNS, as it is not a formal M&A document (TAR) but a market update on the process. Given the context of tender offers, TAR (M&A Activity) is also highly relevant. Since the core subject is the tender offer extension, TAR is a stronger fit than the general RNS fallback.
2022-11-29 English
Half-year Report
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Interim Results for the six months ended 30 September 2022' and contains detailed financial performance metrics, including net assets, portfolio valuation, and capital base. It also includes management commentary, strategic outlook, and clinical milestones. While it is distributed via an RNS (Regulatory News Service) feed, it contains the substantive financial data and analysis required for an Interim/Quarterly Report (IR) rather than being a mere announcement of a report. H1 2022
2022-11-17 English
Freeline reports Q3 2022 Financial Results
Earnings Release Classification · 98% confidence The document is an RNS announcement from Syncona Limited, noting that its portfolio company, Freeline Therapeutics Holdings plc, announced its financial results and a corporate update for the third quarter ended September 30, 2022. The text explicitly details key financial figures (Cash Position, R&D Expenses, Net Loss) for the nine months ended September 30, 2022, and discusses pipeline prioritization and organizational streamlining. This content structure—a summary of period results, operational updates, and forward-looking statements—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since the document provides the key financial highlights and operational narrative, it fits the definition of an Earnings Release (ER) announcing the results, even though the full details might be in a separate document linked below. It is not a comprehensive, standalone 'Interim Report' (IR) which usually contains full financial statements, but rather the initial announcement of those results. Given the context of an RNS announcement summarizing Q3 results, 'ER' is the most appropriate classification. Q3 2022
2022-11-15 English
Anaveon presents updated data from ANV419
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 0208G' and contains standard regulatory boilerplate language at the end, including references to 'RNS, the news service of the London Stock Exchange' and compliance with the Financial Conduct Authority. The content is a press release from Syncona Limited regarding an update from its portfolio company, Anaveon, about clinical data presented at a medical conference (SITC 37th Annual Meeting). This format—a brief announcement of company news, often referencing where the full details or underlying reports can be found (like on Anaveon's website or the SITC website)—is characteristic of a general regulatory news service announcement, rather than a comprehensive financial report (like 10-K or IR) or a specific management/governance filing. Since it is a general regulatory announcement that doesn't fit the more specific categories (like ER, DIV, DIRS, etc.), the appropriate fallback is Regulatory Filings (RNS). The document length is substantial (over 11,000 characters), but its primary function is to disseminate timely, non-financial-statement news via the RNS system.
2022-11-10 English
Achilles reports Q3 2022 Financial Results
Report Publication Announcement Classification · 99% confidence The document is an RNS announcement (indicated by 'RNS Number : 6821F' and the closing boilerplate referencing RNS and the London Stock Exchange). The primary content is Syncona Limited noting that its portfolio company, Achilles Therapeutics Plc, announced its 'Q3 2022 Financial Results and Business Highlights'. The text then contains the full text of Achilles' announcement, which includes condensed financial statements (Balance Sheets and Statements of Operations) for the third quarter ended September 30, 2022. Since this document is an announcement *about* the release of quarterly financial results, and it contains the detailed financial tables, it is best classified as an Interim/Quarterly Report (IR) rather than just an Earnings Release (ER) which is typically just highlights, or an RPA which usually just points to the report. However, the structure is that Syncona is reporting on Achilles' results. Given the presence of the full financial tables and the specific mention of 'Third Quarter' results, it strongly aligns with the content of an Interim Report (IR). If the document were purely Syncona's own quarterly report, IR would be definitive. Since it's a holding company reporting on a portfolio company's quarterly results, and the content is substantial financial data, IR is the most appropriate fit among the options for comprehensive period reporting.
2022-11-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.